C
STOK icon

Covestor’s Stoke Therapeutics STOK Stock Holding History

Covestor’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
16
+12
+300% +$385 ﹤0.01% 2337
2026
Q1 		$0 Buy
+4
New +$131 ﹤0.01% 2744
2025
Q2 		– Sell
-2,417
Closed -$16K – 2737
2025
Q1 		$16K Buy
+2,417
New +$22.5K 0.01% 1269

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Covestor's STOK Position: Q2 2026 in Review

Covestor increased its Stoke Therapeutics (STOK) stake by 300% in Q2 2026, buying an estimated $385 and bringing the position to 16 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2337.

Covestor first reported a position in STOK in Q1 2025 and has held it in 3 quarters since. The position peaked at $16K in Q1 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Covestor held 16 shares of Stoke Therapeutics worth $1K as of Q2 2026.
  • Covestor bought 12 Stoke Therapeutics shares in Q2 2026, an estimated $385.
  • Stoke Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2337 holding.
  • Covestor first reported a position in Stoke Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Covestor's Stoke Therapeutics position peaked at $16K in Q1 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.